What You Should Know:
– Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care announces the availability of NorstellaLinQ on the Atropos Evidence Network.
– Norstella, one of the largest global pharma intelligence solution providers, is already adopting Atropos Health’s Generative AI platform, GENEVA OS™ (Generative Evidence Acceleration Operating System) and is further expanding its partnership with Atropos Health by adding NorstellaLinQ to the Atropos Evidence Network.
Atropos Health Expands Evidence Network with NorstellaLinQ for Enhanced Real-World Data Insights
Atropos Health, the developer of GENEVA OS™, the premier operating system for real-world healthcare evidence, continues to transform healthcare by closing evidence gaps and advancing data-driven care. Through its Atropos Evidence Network, the largest federated data network in healthcare with over 300 million patient records, the company enables:
- Life sciences leaders to generate real-world evidence (RWE) for drug development, clinical trial recruitment, physician targeting, and market sizing.
- Health system leaders and clinicians to leverage high-quality real-world data (RWD) for shared decision-making and care protocol design.
- Healthcare AI developers to build, test, and deploy AI models using robust clinical datasets.
The integration of NorstellaLinQ, a comprehensive dataset with hundreds of millions of U.S. patient records, further enhances the Atropos Evidence Network. This dataset, composed of open medical and pharmacy claims, is particularly rich in diagnosis and procedure data and demonstrates high Real World Fitness Score® (RWFS) ratings for applications in commercialization, health economics and outcomes research (HEOR), and R&D. It is especially valuable in rheumatology, oncology, and cardiology, enabling the re-examination of studies across multiple therapeutic areas.
Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health, emphasized the impact of this partnership, stating that the addition of high-quality datasets like NorstellaLinQ strengthens the healthcare industry’s ability to advance evidence-based medicine. Norstella has also benefited from the Data Quality Scorecard provided to all data holders in the Atropos Evidence Network, offering objective scoring, benchmarking, and improvement insights based on methodologies published in MedRxiv.
This announcement follows Atropos Health’s recent partnerships with Arcadia, Xcures, and Scipher, further expanding the network’s diversity and quality of real-world data. By integrating industry-leading datasets and fostering collaborations, Atropos Health continues to set the standard for timely, relevant, and high-impact real-world evidencein healthcare and life sciences.
